Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Centessa Pharmaceuticals plc - American Depositary Shares (NQ:CNTA)

22.90 +0.04 (+0.17%)
Streaming Delayed Price Updated: 2:46 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Centessa Pharmaceuticals plc - American Depositary Shares

< Previous 1 2 3 4 5 6 Next >
CENTESSA PHARMACEUTICALS-ADR (NASDAQ:CNTA) Shows Strong Technical Setup for Potential Breakout
CNTA stock shows strong technical momentum and a high-quality consolidation pattern, signaling a potential breakout for traders. 
Via Chartmill
3 Biotech Stocks Showing Strength With Big Spikes In Momentum Scores
A handful of biotech stocks are showing renewed strength, with big spikes in their Benzinga Edge Ranking's Momentum scores. 
Via Benzinga
Centessa Pharmaceuticals to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Alkermes Offers The Next Proof Point For Its Narcolepsy Approach. Stock Dives.
All four companies are testing out orexin agonists to improve the symptoms of narcolpesy. 
Via Investor's Business Daily
Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025
From Centessa Pharmaceuticals plc
Via GlobeNewswire
This Centessa Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Thursday
 
Via Benzinga
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting
From Centessa Pharmaceuticals plc
Via GlobeNewswire
AeroVironment Posts Downbeat Results, Joins Box, CrowdStrike And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
 
Via Benzinga
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Why Twilio Shares Are Trading Higher By Over 18%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Cassava Sciences, Biohaven And Other Big Stocks Moving Lower In Monday's Pre-Market Session
 
Via Benzinga
Maximus Reports Weak Earnings, Joins Atkore, PDD Holdings And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
 
Via Benzinga
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Wake Up to This Biotech Stock That Still Has Big Potential Upside
Centessa Pharmaceuticals released strong results in Phase 1 trials and now Wall Street analysts are buzzing over the stock. 
Via MarketBeat
Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Sleep-Disorder Focused Centessa Pharmaceuticals Unveils Interim Data From Lead Program In Acutely Sleep-Deprived Healthy Volunteers
Centessa Pharmaceuticals revealed promising interim Phase 1 trial results for ORX750, demonstrating significant improvements in sleep latency for acutely sleep-deprived healthy volunteers. The company... 
Via Benzinga
Calavo Growers Posts Better-Than-Expected Earnings, Joins Tesla, Oracle, Mission Produce And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
Centessa Rockets To Three-Year High On $5 Billion Narcolepsy Opportunity
The company tested a potential narcolepsy treatment in healthy, but sleep-deprived, volunteers. 
Via Investor's Business Daily
Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
ORX142 is currently in IND enabling activities for select neurological, neurodegenerative, and psychiatric disorders with excessive daytime sleepiness (EDS) 
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Centessa Pharmaceuticals to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From Centessa Pharmaceuticals plc
Via GlobeNewswire
CNTA Stock Earnings: Centessa Pharmaceuticals Misses EPS for Q2 2024
CNTA stock results show that Centessa Pharmaceuticals missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.